Sanofi Logo
  1. Home
  2. Home
  3. About Mozobil

What EfficientMobilizationCan Mean for Your Patients

Efficient mobilization is more relevant than ever.1 Learn how Mozobil + granulocyte-colony stimulating factor (G-CSF) may help decrease the number of apheresis days required for patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) compared to G-CSF alone.2-4

Indication and Usage

Mozobil 1

Mozobil is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with NHL or MM.2

Mozobil is a first in class CXCR4 receptor antagonist.2

Mozobil + G-CSF Decreased the Number of Apheresis Days Compared With G-CSF Alone2

Study Design

Two phase 3, multicenter, randomized, double-blind, placebo-controlled studies evaluated the efficacy and safety of Mozobil (0.24 mg/kg) + G-CSF (10 μg/kg) vs placebo + G-CSF (10 μg/kg) in patients with MM (N=302) or NHL (N=298)2-4

Primary End Point

Mozobil 1

Mozobil + G-CSF Helped Achieve Greater Day One Collection for Patients With MM3

Mozobil + G-CSF Demonstrated a >3-Fold Greater Day One Collection Compared With G-CSF Alone3

Secondary End Point

Kaplan-Meier Estimate of the Proportion of Patients With MM Who Achieved ≥6 x 106 CD34+ cells/kg, by Apheresis Day3

Kaplan-Meier estimate of the percentage of MM patients who achieved greater than or equal to 6x106 CD34+ cells/kg, by Apheresis Day

>50% of patients with MM achieved ≥6 x 106 CD34+ cells/kg in 1 day with Mozobil + G-CSF vs 4 days with G-CSF alone2

Kaplan-Meier Estimate of the Proportion of Patients With NHL Who Achieved ≥5 x 106 CD34+ cells/kg, by Apheresis Day4

Kaplan-Meier estimate of the percentage of NHL patients who achieved greater than or equal to 5x106 CD34+ cells/kg, by Apheresis Day.

>50% of patients with NHL achieved ≥5 x 106 CD34+ cells/kg in 3 days with Mozobil + G-CSF vs <30% reaching the collection target in 4 days with G-CSF alone2

Mozobil 1

Mozobil + G-CSF Allowed More Patients to Proceed to HCT3,4

Secondary End Point: Post Hoc Analysis*

Percentage of Patients With MM Who Proceeded to HDT/HCT Based on Their Mobilization Regimen3

Percentage of patients with NHL who proceeded to HDT/HCT based on their mobilization regimen.

Percentage of Patients With NHL Who Proceeded to HDT/HCT Based on Their Mobilization Regimen4

Percentage of patients with NHL who proceeded to HDT/ASCT based on their mobilization regimen.

*Patients with MM or NHL receiving Mozobil + G-CSF vs patients receiving G-CSF alone, who underwent transplant based on achievement of a minimum number of collected cells.3,4

  • Multiple factors can influence time to engraftment and graft durability following HCT2
  • For transplanted patients in the Phase 3 studies, time to neutrophil and platelet engraftment and graft durability were similar across the treatment groups2

Mozobil + G-CSF Has an Established Safety Profile2-4

Mozobil 1

Adverse Reactions in ≥10% of Patients With NHL and MM Receiving Mozobil + G-CSF or Placebo + G-CSF During HSC Mobilization and Apheresis2

*Grades based on criteria from the World Health Organization.

Mozobil Reversibly Blocks the CXCR4/SDF-1α Interaction2

Image showing CD34+ stem cell anchored to bone marrow.
Image showing Mozobil disrupting CXCR4 and SDF-1α interaction which leads to CD34+ stem cell release in the bloodstream.
  • Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules2
  • As an inhibitor of the CXCR4 chemokine receptor, Mozobil reversibly blocks binding of its cognate ligand, SDF-1α2
  • This action allows the release of stem cells from the bone marrow into the circulating blood2
Mozobil 1

Dosing and Administration

See the details around recommended dosage and when to administer Mozobil.

get the information

Support

Sanofi Patient Connection is a
support program designed to assist your patients.

see the details

Abbreviations: CXCR4, C-X-C motif chemokine receptor 4; G-CSF, granulocyte-colony stimulating factor; HCT, hematopoietic cell transplantation; HDT, high-dose therapy; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma; SDF-1α, stromal-derived growth factor 1α.

References:

  1. Al Saleh AS, Sher T, Gertz MA. Multiple myeloma in the time of COVID-19. Acta Haematol. 2020;17:1-7.
  2. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2020.
  3. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.
  4. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  5. Giralt S, Costa C, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295-308.